

COMPLETE LISTING OF THE CLAIMS

In the claims, please amend claims 1 and 30 as follows:

1. (currently amended) A process for delivering a molecule to an extravascular cell in a mammalian target tissue in vivo comprising: inserting an injection solution containing the molecule into the lumen of an efferent or afferent vessel of the target tissue wherein the volume of the injection solution and the rate of injection solution insertion ~~result in~~ cause transient increased vascular permeability in the target tissue, increased ~~tissue size and~~ extravascular fluid volume within the target tissue, swelling of the target tissue, and extravasation of the molecule via the increased vascular permeability, [[and]] resulting in delivery of the molecule to the extravascular cell.
2. (original) The process of claim 1 wherein fluid flow out of the target tissue is occluded.
3. (canceled)
4. (original) The process of claim 1 wherein the molecule consists of a biologically active compound.
5. (original) The process of claim 1 wherein the molecule consists of a macromolecule.
6. (original) The process of claim 5 wherein the macromolecule is greater than 5 kDa.
7. (original) The process of claim 6 wherein the macromolecule is greater than 30 kDa.
8. (original) The process of claim 7 wherein the macromolecule is greater than 500 kDa.
9. (original) The process of claim 1 wherein the molecule consists of a protein.
10. (original) The process of claim 1 wherein the molecule consists of a peptide.
11. (withdrawn) The process of claim 1 wherein the molecule consists of a polymer.
12. (original) The process of claim 1 wherein the molecule consists of a therapeutic molecule.
13. (original) The process of claim 1 wherein the molecule is in a complex.
14. (original) The process of claim 1 wherein the injection solution contains a compound that increase vessel permeability.
15. (original) The process of claim 14 wherein the compound consists of a vasodilator.
16. (original) The process of claim 1 wherein the cell consists of a liver cell.
17. (original) The process of claim 16 wherein the liver cell consists of a hepatocyte.
18. (original) The process of claim 1 wherein the cell consists of a skeletal muscle cell.
19. (original) The process of claim 1 wherein the cell consists of a heart muscle cell.

20. (original) The process of claim 1 wherein the cell consists of a prostate cell.
21. (original) The process of claim 1 wherein the vessel consists of a blood vessel.
22. (original) The process of claim 21 wherein the blood vessel consists of an artery.
23. (original) The process of claim 21 wherein the blood vessel consists of a vein.
24. (original) The process of claim 1 wherein the vessel consists of a bile duct.
25. (original) The process of claim 1 wherein the injection solution contains less than 20 mM salt.
26. (original) The process of claim 25 wherein the injection solution contains less than 5 mM salt.
27. (original) The process of claim 1 wherein the injection solution contains zwitterions.
28. (withdrawn) The process of claim 1 wherein the injection solution is hypotonic.
29. (original) The process of claim 1 wherein the injection solution is hypertonic.
30. (currently amended) [[An]] A process for delivering a molecule to an extravascular in vivo mammalian cell in a target tissue comprising: rapidly inserting a sufficient volume of injection solution containing the molecule into the lumen of an efferent or afferent vessel of the target tissue at an appropriate rate and impeding fluid flow away from the tissue during the injection such that extravascular fluid volume in the tissue and size of the tissue are is transiently increased, resulting in swelling of the target tissue, increased vascular permeability in the target tissue, extravasation of the molecule and delivery of the molecule to the extravascular mammalian cell in the tissue.